Physician profile
Andy E Walker
NPI 1255436812
$2,872.69
in general payments reported to CMS, 2019-2025
30 companies · $24.93 in 2025
The $24.93 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $357 · 2020: $571 · 2021: $1,257 · 2022: $451 · 2023: $100 · 2024: $112 · 2025: $24.93.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $237.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $237.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $821.98 | 2019-2024 | Evenity, Prolia, Repatha |
| Abbvie INC. | $399.29 | 2021-2024 | |
| Biohaven Pharmaceuticals, INC. | $329.46 | 2020-2021 | |
| Lilly USA, LLC | $273.75 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $213.58 | 2019-2022 | |
| Novo Nordisk INC | $108.73 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $80.66 | 2021-2022 | |
| Pfizer INC. | $77.74 | 2020-2021 | |
| Electromed, INC. | $71.01 | 2021 | |
| Astellas Pharma US INC | $53.20 | 2019-2021 | |
| Radius Health, INC. | $47.36 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $41.07 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $35.45 | 2019 | |
| Allergan, INC. | $33.91 | 2020 | |
| Eisai INC. | $31.26 | 2020-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.36 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $25.57 | 2022 | |
| Philips North America LLC | $24.93 | 2025 | Vest Therapy Und |
| Smith+Nephew, INC. | $21.16 | 2019 | |
| Lundbeck LLC | $20.49 | 2022 | |
| Resmed Corp | $17.33 | 2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.87 | 2022 | |
| Roche Diagnostics Corporation | $13.80 | 2019 | |
| Linus Health, INC. | $13.38 | 2024 | Core Cognitive Evaluation |
| Ultragenyx Pharmaceutical INC. | $12.78 | 2021 | |
| Paratek Pharmaceuticals, INC. | $12.60 | 2021 | |
| Esperion Therapeutics, INC. | $12.13 | 2020 | |
| Siemens Medical Solutions USA, INC. | $11.98 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $11.91 | 2022 | |
| Melinta Therapeutics, LLC | $10.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andy Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.